Mofegiline

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mofegiline
Mofegiline.svg
Clinical data
Synonyms MDL-72,974A
Routes of
administration
Oral[1]
ATC code
  • None
Legal status
Legal status
  • Development terminated
Pharmacokinetic data
Biological half-life 1–3 hours[1]
Excretion Urine[2]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C11H13F2N
Molar mass 197.224 g/mol
3D model (JSmol)

Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]

See also[edit]

References[edit]

  1. ^ a b Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S (September 1995). "Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial". Clinical Pharmacology and Therapeutics. 58 (3): 342–53. doi:10.1016/0009-9236(95)90252-X. PMID 7554709. 
  2. ^ Dulery BD, Schoun J, Zreika M, et al. (March 1993). "Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man". Arzneimittel-Forschung. 43 (3): 297–302. PMID 8489556. 
  3. ^ Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A (1988). "Design and early clinical evaluation of selective inhibitors of monoamine oxidase". Progress in Neuro-psychopharmacology & Biological Psychiatry. 12 (6): 967–87. doi:10.1016/0278-5846(88)90092-9. PMID 3266532. 
  4. ^ Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG (1989). "MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 1 (4): 243–54. doi:10.1007/bf02263478. PMID 2597310. 
  5. ^ Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G (1994). "Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential". Journal of Neural Transmission. Supplementum. 41: 407–14. doi:10.1007/978-3-7091-9324-2_54. ISBN 978-3-211-82521-1. PMID 7931257. 
  6. ^ Thiffault C, Quirion R, Poirier J (March 1998). "Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain". Synapse. 28 (3): 208–11. doi:10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID 9488505. 
  7. ^ Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 1370. ISBN 978-0-412-46630-4. Retrieved 25 November 2011.